On January 22, 2025, Insilico Medicine announced that a mesothelioma patient has received the first dose of its new treatment ISM633 in an ongoing trial.<\/p>\n
Mesothelioma<\/a> is a rare and aggressive cancer that\u2019s very hard to treat. The need for new therapies remains urgent, and ISM6331 could be a promising option if it shows benefits in clinical trials.<\/p>\n The drug works by stopping mesothelioma cells from growing and spreading, with the goal of helping patients with advanced cancer live longer.<\/p>\n Right now, Insilco\u2019s phase I clinical trial<\/a> is recruiting mesothelioma patients in China and will soon be enrolling stateside.<\/p>\n “We will move forward to advance patient enrollment in the United States and accelerate the clinical translation to deliver innovative therapies that address unmet medical needs.” Find out more about ISM6331, how it works, and how close it is to reaching patients like you.<\/p>\n ISM6331 is a promising new therapy for mesothelioma and other cancers. It works by blocking a protein called TEAD that helps cancer cells grow.<\/p>\n It’s already shown strong potential to fight metastatic cancer that\u2019s spread to other parts of the body, possibly making it one of the most effective treatments of its kind.<\/p>\n Along with shrinking tumors, ISM6331:<\/strong><\/p>\n \u201cThe potential applications are vast, including the promising enhancement of chemotherapy<\/a> efficacy, bolstering tumor immunity,<\/strong> improving small molecule targeting, and overcoming current drug resistance challenges,\u201d explained Dr. Feng Ren, co-CEO and Chief Scientific Officer of Insilico.<\/p>\n Get our Free Mesothelioma Guide<\/strong> now to learn more about different treatments that could help you or someone you love.<\/p>\n When ISM6331 blocks the TEAD protein, it helps restore balance to the Hippo signaling pathway, which controls cell growth and division.<\/p>\n Mesothelioma patients often have mutations in the NF2 gene, which disrupts the Hippo pathway and allows cancer cells to grow and spread.<\/p>\n The Hippo pathway affects:<\/strong><\/p>\n \u201cAbout 10% of cancer patients are affected by abnormalities in the Hippo signaling pathway,\u201d explained Dr. Ren. \u201cBy inhibiting TEAD, ISM6331 has the potential to suppress tumor growth and progression.<\/strong>\u201d<\/p>\n Even better, ISM6331 may have broad benefits when combined with chemotherapy, immunotherapy<\/a> (which works by boosting the immune system), and targeted therapy<\/a> (which works by attacking specific substances in cancer cells).<\/p>\n Adding ISM6331 to treatment plans could possibly kill more mesothelioma cells or help patients if their cancer doesn\u2019t respond to other therapies.<\/p>\n
\n\u2013 Dr. Sujata Rao, Chief Medical Officer of Insilico Medicine<\/strong><\/p><\/blockquote>\nWhat Is ISM6331?<\/h2>\n
\n
How Does ISM6331 Work?<\/h2>\n
\n
ISM6331 Treatment Timeline: What Comes Next?<\/h2>\n